Project Grant R01HL175081
Award Date 8/1/25
Completion Date 4/30/29
Dollars Obligated $587K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Antonio, TX 78229, USA
Similar Awards
- This federal Project Grant award of $1,119,410.00 was provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports a multi-disciplinary research initiative to investigate longitudinal changes in DNA methylation (LC-DNAM) and its relationship to cardiovascular disease (CVD) risk factors and outcomes across four large population-based cohort studies - ARIC, CARDIA, FHS, and MESA. The research aims to: 1)...
- The Texas A&M University System Health Science Center received a $542,663 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to conduct research on the mechanistic role of small Rho GTPase in chronic cardiac fibrotic remodeling. The research aims to explore the dynamic function of fibroblast RhoE in post-myocardial infarction cardiac remodeling, with the goal of selectively mitigating prolonged fibrosis without interrupting...
- The University of Arizona was awarded a $625,316 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to investigate the role of RNA methylation and translational regulation in the oxidative stress response of heart failure. The research aims to elucidate how the YTHDF2 protein binds to methylated NRF2 mRNA to selectively induce its translation under oxidative stress, a process that may be impaired in end-stage heart failure. The...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) is funding research at the University of Arizona to investigate whether and how the hepatocyte protein TMEM141 regulates lipoprotein metabolism and atherosclerosis. The $744,453 award, which runs from August 1, 2025 through May 31, 2029, will utilize genetically modified mouse models and state-of-the-art techniques to study the role of TMEM141 in lipid and lipoprotein...
- The Project Grant award titled "STRUCTURE, FUNCTION AND DRUG TREATMENT OF THE NATIVE CARDIAC SARCOMERE IN HYPERTROPHIC CARDIOMYOPATHY" is funded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) for $149,804. The award aims to utilize advanced cryo-electron tomography (cryo-ET) imaging techniques to directly observe how hypertrophic cardiomyopathy (HCM)-causing mutations and the HCM drug mavacamten affect the structure and function of...
- This $713,511 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research into the impact of myosin-binding protein C (MyBP-C) on myosin mobility and proteostasis in the context of hypertrophic cardiomyopathy (HCM). The University of Vermont & State Agricultural College, the awardee, will utilize innovative techniques to investigate how reduced MyBP-C levels, a common cause of HCM, may disrupt normal heart...
- The National Heart, Lung, and Blood Institute (NHLBI), via the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $564,445 Project Grant to the University of Texas Health Science Center at Houston (UTHealth) to fund research on "Targeting Hypoxia-Inducible Factors (HIFs) for Heart and Lung Disease." The 6-year grant, starting on March 1, 2025 and ending on December 31, 2031, supports three complementary research projects focused on investigating the upstream regulation...
- This Project Grant award of $576,786.00, provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports research at the University of Arizona to investigate the role of the YTHD2 protein in regulating the translation of the NRF2 protein under conditions of oxidative stress. The research aims to elucidate the mechanisms by which certain proteins, like NRF2, can continue to be translated despite the general inhibition of protein...
- The University of Arizona, operating as the Arizona Board of Regents, was awarded a $125,385 Project Grant on June 15, 2025 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to investigate the role of mutation-specific calmodulin kinase II (CaMKIID) activation in hypertrophic cardiomyopathy (HCM). The project aims to elucidate the specific biophysical alterations in the cardiac thin filament that trigger increased autonomous CaMKIID activity in...
- This federal Project Grant award, provided by the National Heart Lung and Blood Institute under CFDA Program 93.837 Cardiovascular Diseases Research, supports research into the mechanical regulation of hematopoiesis and osteogenesis in the bone marrow. The $152,324 grant, awarded on January 15, 2025 with a final completion date of August 31, 2027, will enable the University of Texas Southwestern Medical Center to investigate the role of the mechanically regulated ion channel TREK1 in...